thought call
given investor concern humira ou eros rate modest
miss like provid littl reassur trajectori
compani top- bottom-lin anyth manag tone
downward revis y/i declin vs prior opinion like
signal full extent biosimilar impact may even larger model
y/i commerci admittedli still latitud us humira
sale growth guidanc y/i capabl anchor near term
outlook rest portfolio less encouragingespeci given
view overli optimist hcv guidanc y/i vs limit uptak
project orilissa still despit overhang near-term sign
encourag number potenti regulatori clinic win could potenti
like approv upadacitinib
risankizumab yearand prodigi balanc sheet remain
capabl stabil share although manag stress larger-scal deal
unlik think major growth asset would improv investor sentiment especi
given question upsid current pipelin absent signific bd howev
concern humira like weigh share lower price
target vs prior reflect humira uncertainti maintain ew
pipelin updat multipl phase read-out expect venclexta
includ detail data cll top-lin result r/r mm bellini
two aml set phase data also like depatux-m glioblastoma
orilissa uf regulatori submiss plan mid-year
model updat given updat comment guidanc adjust
revenu forecast respect
prior base adjust opex estim adjust ep
respect vs prior
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg behind us due settlement
less concern futur
franchis pipelin beyond core
product interest like success
unsur enough make revenu
come introduct humira biosimilar
pipelin success multipl asset indic
would drive revenu thu share price upsid
lessen impact humira biosimilar could also
wors expect impact humira biosimilar
entrant competit prior amgevita
failur pipelin asset could also hamper long-term
price target updat follow manag updat revis price target
downward prior valu use discount cash
flow analysi assum wacc vs prior impli intrins valu
million except per share itemspriorcurrentpriorcurrenthumira non-oper incom ep barclay abbvi inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
